KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Payables (2016 - 2025)

AbbVie (ABBV) has disclosed Payables for 14 consecutive years, with $37.2 billion as the latest value for Q4 2025.

  • Quarterly Payables rose 16.55% to $37.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.2 billion through Dec 2025, up 16.55% year-over-year, with the annual reading at $37.2 billion for FY2025, 16.55% up from the prior year.
  • Payables for Q4 2025 was $37.2 billion at AbbVie, roughly flat from $37.4 billion in the prior quarter.
  • The five-year high for Payables was $37.4 billion in Q3 2025, with the low at $20.6 billion in Q1 2021.
  • Average Payables over 5 years is $27.8 billion, with a median of $28.2 billion recorded in 2023.
  • The sharpest move saw Payables soared 62.12% in 2021, then rose 2.81% in 2024.
  • Over 5 years, Payables stood at $22.7 billion in 2021, then rose by 11.84% to $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then grew by 4.23% to $31.9 billion in 2024, then grew by 16.55% to $37.2 billion in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $37.2 billion, $37.4 billion, and $34.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.